Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients

(University of Texas M. D. Anderson Cancer Center) A metabolic inhibitor drug, IACS-6274, developed by MD Anderson's Therapeutics Discovery division, is well-tolerated and showed early signs of anti-tumor activity in a Phase I trial being presented at the 2021 ASCO Annual Meeting.